The case for & against
Bull & Bear analysis
Bullish
Evolus, Inc. (NASDAQ: EOLS) is a growing player in the aesthetic medical products market, focusing on developing and commercializing advanced injectable solutions, particularly neurotoxins and hyaluronic acid products. The company has successfully expanded its product offerings, enhancing its market position and addressing demand in both domestic and international markets, marking it as a significant participant in the aesthetic treatment industry.
Bull says
- ↑Q2 2026 revenue rose 21% YoY to $84.1M, beating EPS by 156.8%
- ↑Adjusted EBITDA reached $4.7M for the third straight quarter
- ↑US licensing of Profilo and Esteem launch in Europe drive ~69% pipeline growth
- ↑Institutions hold strongly, underpinning a $14.67 fair value target
- ↑High growth and upward earnings revisions factors signal robust momentum
- ↑Cash of $45.2M provides funding flexibility for expansion
Bear says
- ↓Negative earnings yield and low book-to-price ratio indicate stretched valuation
- ↓Leverage remains high, risking debt service if growth slows
- ↓Underlying profitability factors weak despite EBITDA gains
- ↓Share volatility score elevated, risking sharp price moves
- ↓Regulatory approvals for new products like Profilo may delay growth
- ↓Small size and lower liquidity could constrain capital access
Investment themes with EOLS
Pharmaceuticals↓ -0.48%
Drug development driving global healthcare solutions
JNJ · LLY · RPRX
Earnings Call · Q2 2023 · Mgmt. Guidance
Updated 11-30-2024bullish
Transcript signals
Bull points
- So, we do expect the back half of the year to also be very strong, if not pick up a tick from what we've seen in the front half.
- we continue to see a very favorable trend where existing customers are willing to commit more of their business to Jeuveau as they gain confidence with our brand and they participate in the benefits of our advertising which is a key driver, especially when they're looking for growth.
- We're in the process now of Rui and his team taking over all of the clinical development and the exchange with the FDA, and we're really pleased with the progress that team has made, and we feel very confident in our ability to deliver on an approval in 2025.
Bear points
- Our non-GAAP loss from operations in the second quarter was $8 million compared to $5.9 million reported in the first quarter. Non-GAAP loss from operations this quarter includes the $4.4 million license milestone expense.
Read full transcript analysis ›